Feed

RNA

Avidity Biosciences

RNA · NASDAQ

$10.09 -1.18% (-$0.12)

1M -22.15%

Piotroski F-Score Weak

2/9

Valuation

N/A

PEG N/A

P/E N/A

P/FFO N/A

Growth

N/A

FCF growth N/A

EPS growth N/A

Book val. growth N/A

Profitability

N/A

Op. margin N/A

Gross margin N/A

FCF margin N/A

Quality

N/A

ROA N/A

ROIC N/A

Asset turnover N/A

Debt

N/A

Int. coverage N/A

Debt/Equity N/A

Net debt/EBITDA N/A

Stability

42 /100

Moderate

Beta 0.37x

Profitable years N/A

Rev. volatility N/A

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RNA

Online

About the company

Avidity Biosciences is a biotechnology company focused on developing advanced therapeutic methods using targeted RNA-based therapies. The company specializes in creating therapeutic products that leverage its proprietary technologies to selectively deliver therapeutic molecules to specific cells, offering a new approach to treating diseases caused by genetic mutations. Avidity focuses on treating diseases such as Duchenne muscular dystrophy and other genetic disorders that previously lacked effective treatments.

Sector

Healthcare

Industry

Biotechnology

CEO

Kathleen Gallagher

Employees

511

Headquarters

San Diego

Upcoming events

12 NOV

Earnings

Upcoming earnings report

57d

⌘ K

StockBot Live

Market situation Wall Street

Wall Street opens higher on Fed decision day

The S&P 500 +0.40% and Nasdaq +0.60% opened higher. Europe's DAX +0.35% rose ahead of the Fed rate hike.

Ask about this

StockBot knows 80,000+ stocks worldwide